Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
which Bristol Myers Squibb acquired in March 2024. At Karuna, he served as Senior Vice President of Regulatory Affairs and ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
24/7 Wall St. on MSN22h
Can This Dividend King Ever Hit $400 After This Major Fail?AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...
On September 16, 2024, Immatics announced the proof-of-concept clinical data for the first candidate of its next-generation, ...
An Investigational New Drug application for the Nectin4/TROP2 ADC is planned for submission to the U.S. Food and Drug Administration in ... played an integral role in its acquisition by Bristol Myers ...
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the "Company”) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback